The FDA should work to modify its reputation from that of an organization that merely approves drugs or inspects production facilities to a public-health agency focused on preventing illness, FDA Commissioner Dr. Margaret Hamburg wrote in an editorial in the New England Journal of Medicine. The article, co-authored by FDA Deputy Commissioner Dr. Joshua Sharfstein, also emphasized the need for policies to ensure safety in product approval, including conducting post-market studies of drugs and devices.

Related Summaries